In addition to the patents held for healthcare-based enclosed space disinfection applications, Medizone International, Inc. has now been awarded a patent for its government variant of AsepticSure, intended for use by defense agencies as a response to a biological attack on critical buildings, infrastructure and resources.
“We have been successful in completely eliminating Bacillus atropheus and Bacillus subtilis, both internationally recognized study surrogates for Anthrax, one of the most difficult weaponized pathogens to kill,” explained Dr. Michael E. Shannon, Medizone International’s President. “Being able to eliminate these surrogates for Anthrax with our technology almost assures we now have the ability to remediate critical public infrastructure following a biological attack and restore it to service without damaging important and expensive equipment including communications systems. Militaries have struggled with this problem for decades and, until now, this simply has not been possible.”
“To now have patent protection granted for this system,” stated Edwin Marshall, Medizone’s CEO, “should allow the Company protected access to a potentially lucrative government market due to the unique capability of AsepticSure’s government variant.”
Medizone International, Inc. is a research and development company advancing systems to decontaminate and sterilize hospital surgical suites, emergency rooms, intensive care units, schools and other critical infrastructure. Medizone International’s BSL2A certified laboratory located at Innovation Park, Queen’s University in Kingston, Ontario, Canada, provides a primary research and development platform for the company.
